Loading...
•
Dec 31, 2021
Jaguar Health Q4 2021 Earnings Report
Reported company updates and consolidated financial results.
Key Takeaways
Jaguar Health reported increased Mytesi net revenue in Q4 2021, driven by the transition to a closed network of specialty pharmacies.
Mytesi net revenue was approximately $2.1 million in Q4 2021, compared to $0.6 million in Q3 2021, representing a 230% increase.
The increase in Mytesi net revenue was largely due to the transition to distributing Mytesi through a closed network of specialty pharmacies.
Mytesi new prescription volume increased 10.4% in Q4 2021 over Q3 2021.
Completed transition of Mytesi volume to a closed network of specialty pharmacies in January.
Jaguar Health
Jaguar Health
Forward Guidance
Jaguar Health is focused on continued development of crofelemer, forging license and business development relationships, continuing the Canalevia-CA1 launch, and continuing sales of Mytesi.